In recent years, you may have often heard the term "robotic surgery." While robotic surgery is becoming increasingly common in many hospitals, unfortunately, the development of surgical robots for ophthalmology has lagged behind.


Eye surgery involves performing delicate tasks in an extremely confined space while looking through a microscope. As a result, there was physically no room for large robots. Additionally, it was challenging for assistants to help with the surgery, requiring surgeons to hold both the surgical tools and the light source illuminating the inside of the eye by themselves.
This led us to conceive the "Intraocular Tool Holding Robot." We believed that if there was a safe way to hold intraocular tools, surgeons could perform surgical procedures using both hands.
Subsequently, with support from various sectors, we proceeded with research and development as follows:
・AMED (Japan Agency for Medical Research and Development) Translational Research/New Development Seeds (Seeds A)
・AMED "Medical Device and System Development Project for Future Medicine"
・Basic patent + 6 related patents obtained
・Product development following PMDA (Pharmaceuticals and Medical Devices Agency) preliminary consultation
・General medical device sales notification accepted
This led to the creation of OQrimo® , the world's first ophthalmologic surgical assistance robot. OQrimo® is a pioneering surgical assistance robot that enables surgeons to use both hands freely by safely holding either intraocular illumination or an intraocular endoscope.


The device can be operated intuitively using a touch panel interface.
The endoscope screen displays a guide showing the current viewing position for improved visibility. When OQrimo is moved using the foot switch, the guide moves simultaneously.
After OQrimo®'s market launch in April 2023, we proceeded through appropriate procedures for its first clinical use:
December 2023: 1st successful clinical use
2024: 8 successful clinical use
These first 9 surgical procedures were successful, confirming that OQrimo® functions properly in actual clinical settings.
Up to Now:
Safety measures discussed at "Advisory Meetings" hosted by Riverfield
・Safety verification using model eyes, preparation of licensing system and technical training framework
Initial clinical use begun at various facilities
Going Forward:
Creation of "Proper Use Manual" detailing applicable conditions and optimal techniques
Wider use by licensed physicians to begin at a later stage
Transition to "Physician-led Research Group" independent of corporate involvement
・Safety monitoring
・Planning clinical research designs for future development


We will continue to conduct further verification and evaluation, gradually expanding its use while ensuring safety and reliability.

